Nasal spray could offer quick relief for Parkinson's 'Off' moments

NCT ID NCT07156773

Recruiting now Symptom relief Sponsor: Guangzhou Novaken Pharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a new nasal spray called XJN010 for people with Parkinson's disease who have 'off' episodes—times when their regular medication stops working and symptoms return. The trial will include 84 adults aged 30 to 85 and will measure how well the spray improves movement and how long it takes to switch from 'off' to 'on' state. The goal is to see if the spray is safe and effective for managing these difficult episodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XJN010 nasal spray
What this could lead to: If successful, this nasal spray could offer a fast-acting way to reduce the duration and severity of 'off' episodes, improving daily function for people with Parkinson's.
What could go wrong: This is an early Phase 2 trial with only 84 participants, so results may not apply to everyone. The spray may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)
RECRUITING

Guangzhou, Guangdong, 511434, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.